Aphria RX, a subsidiary of Tilray Brands, launched the first commercial medical cannabis flower grown at its facility in Neumünster, Germany.
The launch marks the first medical marijuana products that Aphria RX has grown under the MMJ cultivation license the company received in July under Germany’s Medicinal Cannabis Act (MedCanG), according to a Thursday news release.
The license allows Aphria RX to cultivate and manufacture a range of commercially available medical cannabis in Germany.
Denise Faltischek, Tilray’s chief strategy officer and head of international, said the launch expands Tilray’s presence in medical cannabis cultivation, production and distribution in Germany.
“We reiterate our appreciation for the trust that the German government has placed in Tilray, and we are proud of our Aphria RX team for their groundbreaking work in medical cannabis cultivation and patient care,” Faltischek said in a statement.
Tilray, which has offices in Leamington, Ontario, Canada, and New York, said in July that the cultivation permit was the first to be issued under Germany’s new recreational cannabis law, which took effect April 1.
The law, approved Feb. 23, removed marijuana from the narcotics list, legalized possession for adults of up to 25 grams (0.88 ounces), allowed for “cannabis clubs” and amended Germany’s Medicinal Cannabis Act.
